« Return to Overview

Long-term Data on JAK Inhibitors: Implications for Clinical Management

Developed by CESAS Medical, under the auspices of the University of Glasgow. This activity is supported by unrestricted educational grants from Pfizer Italia S.R.L. and Lilly

Release date:15 March 2019
Expiration date:15 July 2021
Estimated time to complete activity:1 hour
Compatible with all modern internet browsers and mobile devices

EDUCATIONAL OBJECTIVES
After completing this activity, the learner will be able to:

• Review the main adverse events of the JAK inhibitor class
• Examine the data from JAK clinical trials and real-world data
• Discuss how to effectively manage adverse events in everyday clinical practice

TARGET AUDIENCE
This activity is designed for rheumatologists and other healthcare professionals involved in treating patients with rheumatic disease.

PROGRAMME OVERVIEW
JAK inhibitors represent a revolutionary innovation in the treatment of rheumatoid arthritis. The long-term safety of these cytokine signalling agents is still to be fully elucidated. In this activity, Long-term Data on JAK Inhibitors: Implications for Clinical Management, a panel of international experts discuss published data from 2017–18 and key abstracts from ACR 2018, specifically relating to the long-term safety of JAK inhibitors. This course, outlines key safety data relating to JAK inhibitors in the treatment of rheumatoid arthritis. The learner’s understanding of the information presented will be assessed following each of the course modules and in accordance with the learning outcomes.

INSTRUCTIONS FOR PARTICIPATION
Participants must 1) read the activity information; 2) study the educational content; 3) successfully complete post-module assessments with a score of ≥80%; 4) complete the evaluation form. Upon completion of the full activity, a certificate will be made available to download and print.

DISCLOSURE OF CONFLICTS OF INTEREST
CESAS Medical requires faculty, presenters, planners, managers, writers, and any other individuals who are in a position to influence the content of this activity to disclose any real and/or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly reviewed and resolved according to CESAS Medical policy.

ACCREDITATION STATEMENT
The e-learning activity, Long-term Data on JAK Inhibitors: Implications for Clinical Management, organised by CESAS Medical, under the auspices of the University of Glasgow, is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The e-learning activity, Long-term Data on JAK Inhibitors: Implications for Clinical Management, organised by CESAS Medical, under the auspices of the University of Glasgow, is awarded 1 European CME credits (ECMECs).

Each medical specialist should claim only those credits that he/she actually spent in the educational activity. The EACCME is an institution of the European Union of Medical Specialists (UEMS). Only those e-learning materials that are displayed on the UEMS-EACCME website have formally been accredited. Through an agreement between the European Union of Medical Specialists (UEMS) and the American Medical Association (AMA), physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Module	Presenter	Video	Questions
Introduction	Professor Kevin Winthrop Professor of Infectious Diseases, Public Health and Preventive Medicine, and Ophthalmology, Oregon Health and Science University, Oregon, USA Professor Kevin Winthrop received his undergraduate degree in biology from Yale University and completed his MD degree at Oregon Health Sciences University in Portland, Oregon, USA. He obtained a masters degree in epidemiology at University California at Berkeley and completed an infectious disease epidemiology fellowship with the US Centers for Disease Control and Prevention (CDC) before serving as a staff member at CDC. He has co-authored more than 100 publications, many detailing epidemiologic and clinical aspects of infections and other adverse events associated with immune-mediated inflammatory diseases, particularly those related to biologic immunosuppressive therapies. Professor Winthrop also serves on the editorial board of Annals of Rheumatic Diseases, as Section Editor of Current Rheumatology Reports, and as an Associate Editor of BMC Infectious Diseases. Prof. Kevin Winthrop (Bio)	01:52
Opportunistic Infections and Vaccinations	Professor Kevin Winthrop Professor of Infectious Diseases, Public Health and Preventive Medicine, and Ophthalmology, Oregon Health and Science University, Oregon, USA Professor Kevin Winthrop received his undergraduate degree in biology from Yale University and completed his MD degree at Oregon Health Sciences University in Portland, Oregon, USA. He obtained a masters degree in epidemiology at University California at Berkeley and completed an infectious disease epidemiology fellowship with the US Centers for Disease Control and Prevention (CDC) before serving as a staff member at CDC. He has co-authored more than 100 publications, many detailing epidemiologic and clinical aspects of infections and other adverse events associated with immune-mediated inflammatory diseases, particularly those related to biologic immunosuppressive therapies. Professor Winthrop also serves on the editorial board of Annals of Rheumatic Diseases, as Section Editor of Current Rheumatology Reports, and as an Associate Editor of BMC Infectious Diseases. Prof. Kevin Winthrop (Bio)	18:16	4
Cardiovascular Events	Professor Peter Nash Associate Professor, School of Medicine, Griffith University, Australia Peter Nash is Professor at the School of Medicine, Griffith University, Queensland, and Director of the Rheumatology Research Unit on the Sunshine Coast, Australia. He serves on the Scientific Advisory committee and ASMPOC of the Australian Rheumatology Association, having Chaired the Therapeutics and the Professional Affairs committees of the ARA and served on the Therapeutics Committee of the Australia and New Zealand Bone and Mineral Society. In addition, he is a member of the International Steering Committee of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Professor Nash and his group at the Rheumatology Research Unit have been involved with pivotal registration clinical trials for all modern targeted biologic therapies. He has published over 180 peer-reviewed papers and five book chapters, and serves on the editorial board of Annals of the Rheumatic Diseases and RMD Open and acts as reviewer for many rheumatology journals. His special interests include metabolic bone disease and novel therapeutics. Prof. Peter Nash (Bio)	13:13	3
Malignancies	Professor Rieke Alten Head of Department of Internal Medicine, Rheumatology, Schlosspark-Klinik, University Medicine Berlin, Germany Dr Rieke Alten is head of the department of internal Medicine, Rheumatology, Clinical Immunology, Osteology at Schlosspark-Klinik at University Medicine Berlin, where she also serves as the director of the Rheumatology Research Centre. She is a member of the Global Alliance for Patient Access and OMERACT Steering Committee of the Flare in Rheumatoid Arthritis Group. Dr Alten has served as a board member on many occasions for; German Medical Association, the institute for approval of drugs for the German Ministry of Health, “Kaiser-Friedrich-Stiftung” for postgraduate education in Germany and board member of the German Society of Rheumatology. Prof. Rieke Alten (Bio)	11:01	2
Close	Professor Kevin Winthrop Professor of Infectious Diseases, Public Health and Preventive Medicine, and Ophthalmology, Oregon Health and Science University, Oregon, USA Professor Kevin Winthrop received his undergraduate degree in biology from Yale University and completed his MD degree at Oregon Health Sciences University in Portland, Oregon, USA. He obtained a masters degree in epidemiology at University California at Berkeley and completed an infectious disease epidemiology fellowship with the US Centers for Disease Control and Prevention (CDC) before serving as a staff member at CDC. He has co-authored more than 100 publications, many detailing epidemiologic and clinical aspects of infections and other adverse events associated with immune-mediated inflammatory diseases, particularly those related to biologic immunosuppressive therapies. Professor Winthrop also serves on the editorial board of Annals of Rheumatic Diseases, as Section Editor of Current Rheumatology Reports, and as an Associate Editor of BMC Infectious Diseases. Prof. Kevin Winthrop (Bio)	00:38
Evaluation			17

Date of preparation: 15 March 2019